Please assess the completion status of the following clinical trial:

Trial Title: An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Given written informed consent~* Male or female aged ≥ 19~* Primary immune thrombocytopenia (ITP)~* Platelet \<20x10\^9 /L~* Patients who have taken adrenal cortical hormones and/or other immunosuppressive medications should maintain their stable doses before and during this study~Exclusion Criteria:~* Patients who have participate in other interventional study within 30 days~* Inability in written/verbal communication~* Engaged with an elective surgery~* Pregnant or breast-feeding women~* Women of childbearing potential who do not agree with contraception during this study~* Patients who had experienced any hypersensitivity or shock with study drug or active ingredient~* Refractory to immunoglobulin therapy~* Secondary immune thrombocytopenia~  * HIV-associated ITP~ * Lupus-associated ITP~ * Lymphproliferative disease~ * Hepatitis virus carrier~ * Other disease- or infection-associated ITP~* Drug-Induced ITP~* Hereditary thrombopenia (e.g., MYH9 disorders)~* Hemolytic anemia (Positive direct Coomb's test)~* Clinically significant abnormalities of immunoglobulin~* Immunoglobulin A Deficiency~* Immune disorders or deficiency~* Alcohol or drug abuse within 6 months~* Patients who had taken any medications which may effect platelet function or count for at least 2 days prior study entry~* Patients who had administrated with IVIg or anti-D immunoglobulin agents within 1 month~* Patients who had undergone a splenectomy within 2 months~* Clinically significant underlying disease or medical history at investigator's discretion

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Human immunoglobulin intravenous (Type: EXPERIMENTAL): Human immunoglobulin intravenous; GC5107A (IV-Globulin SN Inj. 10%); Day 1: GC5107A, 1g/kg, intravenous Day 2: GC5107A, 1g/kg, intravenous; Starting infusion rate: 0.01mg/kg/min (1mg/kg/min) for first 15 minutes, and then 2-fold increase every 30 minutes by maximum 0.08ml/kg/min (8mg/kg/min). Dosing modification is allowed due to tolerance.

Based on this trial design, predict the completion outcome and termination type (if applicable).